Literature DB >> 27918176

Comparing depression screening tools in persons with multiple sclerosis (MS).

Joshua Hanna1, Jonathan B Santo2, Mervin Blair3, Kathy Smolewska4, Erin Warriner4, Sarah A Morrow1.   

Abstract

OBJECTIVE: Depression is more common among persons with multiple sclerosis (MS) than the general population. Depression in MS is associated with reduced quality of life, transition to unemployment, and cognitive impairment. Two proposed screening measures for depression in MS populations are the Hospital Anxiety and Depression Scale (HADS) and the Beck Depression Inventory-Fast Screen (BDI-FS). Our objective was to compared the associations of the BDI-FS and the HADS-D scores with history of depressive symptoms, fatigue, and functional outcomes to determine the differential clinical utility of these screening measures among persons with MS.
METHOD: We reviewed charts of 133 persons with MS for demographic information; scores on the HADS, BDI-FS, a fatigue measure, and a processing speed measure; and employment status.
RESULTS: Structural equation modeling results indicated the HADS-D predicted employment status, disability status, and processing speed more effectively than did the BDI-FS, whereas both measures predicted fatigue.
CONCLUSIONS: This study suggests the HADS-D is more effective than the BDI-FS in predicting functional outcomes known to be associated with depression among persons with MS. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Year:  2016        PMID: 27918176     DOI: 10.1037/rep0000115

Source DB:  PubMed          Journal:  Rehabil Psychol        ISSN: 0090-5550


  1 in total

1.  Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial.

Authors:  Barbara Seebacher; Birgit Helmlinger; Daniela Pinter; Rainer Ehling; Harald Hegen; Stefan Ropele; Gernot Reishofer; Christian Enzinger; Christian Brenneis; Florian Deisenhammer
Journal:  BMJ Open       Date:  2022-02-07       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.